Definium Therapeutics, Inc. (DFTX) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.49x
Definium Therapeutics, Inc. (DFTX) has a Cash Flow-to-Debt Ratio of -0.49x as of June 2026, meaning its operating cash flow of $-95.41 Million could theoretically repay 0% of its total liabilities ($194.22 Million) in one year. See Definium Therapeutics, Inc. (DFTX) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.49x
Operating CF / Total Liabilities
Operating Cash Flow
$-95.41 Million
USD
Total Liabilities
$194.22 Million
USD
Data as of
Jun 2026
Most recent filing
Definium Therapeutics, Inc. Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Definium Therapeutics, Inc. across 11 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Definium Therapeutics, Inc..
Annual Cash Flow-to-Debt Ratio for Definium Therapeutics, Inc. (2015–2025)
Year-by-year debt coverage analysis for Definium Therapeutics, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.22x | $-131.56 Million | $107.77 Million | ▲ +6.4% |
| 2024 | -1.30x | $-79.13 Million | $60.70 Million | ▲ +6.0% |
| 2023 | -1.39x | $-64.36 Million | $46.41 Million | ▲ +47.2% |
| 2022 | -2.63x | $-50.14 Million | $19.08 Million | ▲ +29.2% |
| 2021 | -3.71x | $-45.82 Million | $12.34 Million | ▲ +11.1% |
| 2020 | -4.18x | $-23.60 Million | $5.65 Million | ▼ -299.2% |
| 2019 | -1.05x | $-208.12K | $198.96K | ▲ +98.8% |
| 2018 | -87.79x | $-722.45K | $8.23K | ▼ -960.4% |
| 2017 | -8.28x | $-665.98K | $80.44K | ▼ -2245.8% |
| 2016 | -0.35x | $-26.64K | $75.47K | ▲ +94.3% |
| 2015 | -6.22x | $-46.56K | $7.49K | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.